Blood Predictive Biomarkers for Nivolumab in Advanced Melanoma
Nivolumab response rate is 40% in metastatic melanoma. Few studies have evaluated pre-treatment biomarkers predictive of response. The aim of this study was to identify potential peripheral blood biomarkers associated with survival in patients with advanced melanoma treated with nivolumab. All advan...
| Main Authors: | , , , , , , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Society for Publication of Acta Dermato-Venereologica
2018-01-01
|
| Series: | Acta Dermato-Venereologica |
| Subjects: | |
| Online Access: |
https://www.medicaljournals.se/acta/content/html/10.2340/00015555-2872
|